Biotech startups that raised Series B in Europe
Updated 16 Nov 2026
Not sure about the data?
Download a free 10-row sample first. No account, no payment.
| Company | City | Last round | Amount | Date |
|---|---|---|---|---|
| T-Therapeutics | Cambridge | Series B | $133.0M | 2026-11-05 |
| Onego Bio | Helsinki | Series B | $28.0M | 2026-10-26 |
| Sava Technology | London | Series B | $36.0M | 2026-10-09 |
| WhiteLab Genomics | Paris | Series B | $26.0M | 2026-10-05 |
| NovaGo Therapeutics | Schlieren | Series B | $29.7M | 2026-08-31 |
| Pixelgen Technologies | Stockholm | Series B | $15.5M | 2026-08-20 |
| Computomics | Tübingen | Series B | $7.3M | 2026-08-18 |
| Vaderis Therapeutics | Basel | Series B | $152.0M | 2026-08-11 |
8 rows of the CSV in 5 of its 18 columns.
- The 249 biotech startups in Europe whose last round is Series B have raised $7.5B in total.
- 22 of them closed their most recent round in the last 12 months, $1.2B combined.
- The largest of those rounds is Windward Bio's $165.0M Series B, dated May 2026.
- The most recent is T-Therapeutics' $133.0M Series B on 5 November 2026.
- HTGF (High-Tech Gruenderfonds) is an investor in 16 of them, more than any other fund.
- Health care is the most common other sector, with 197 companies (79%).
- 8% were founded in 2020 or later; the median founding year is 2013.
- The most common team size is 11 to 50 employees (55% of companies with a recorded size).
Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.
Newest rounds
30 of 249| Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|
| T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge, United Kingdom | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| Onego Bio | Onego Bio produces egg protein through fermentation as a food ingredient. | Biotech | Helsinki, Finland | Series B | $28.0M | 2026-10-26 | $100.6M | European Innovation Council, Business Finland, Tesi +2 | 11 to 50 | 2022 |
| Sava Technology | Sava Technology creates under-skin sensors that continuously monitor glucose, lactate, and ketones. | Biotech | London, United Kingdom | Series B | $36.0M | 2026-10-09 | $62.8M | SOSV, Balderton Capital, Social Starts +1 | 101 to 250 | 2016 |
| WhiteLab Genomics | WhiteLab Genomics builds digital tools that help gene and cell therapy companies develop drugs faster and cheaper. | Artificial intelligence | Paris, France | Series B | $26.0M | 2026-10-05 | $36.5M | Y Combinator, Omnes Capital | 11 to 50 | 2019 |
| NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren, Switzerland | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| Pixelgen Technologies | Pixelgen Technologies develops technologies for biomedical research and diagnostics. | Biotech | Stockholm, Sweden | Series B | $15.5M | 2026-08-20 | $43.5M | Industrifonden, Navigare Ventures, Colibri Ventures +1 | 11 to 50 | 2020 |
| Computomics | Computomics applies artificial intelligence to genomics data to advance agricultural solutions. | Artificial intelligence | Tübingen, Germany | Series B | $7.3M | 2026-08-18 | $10.0M | HTGF (High-Tech Gruenderfonds), VentureOut, European Innovation Council +2 | 11 to 50 | 2012 |
| Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel, Switzerland | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| Mironid | Mironid discovers drugs to treat degenerative kidney diseases, chronic inflammatory diseases, and cancer. | Biotech | Glasgow, United Kingdom | Series B | $45.9M | 2026-08-05 | $90.6M | Scottish Enterprise, Sofinnova Partners, European Investment Fund +1 | 11 to 50 | 2014 |
| NVision Quantum Technologies | NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. | Biotech | Ulm, Germany | Series B | $38.0M | 2026-05-13 | $155.2M | Entrée Capital, European Commission, Playground Global +2 | 101 to 250 | 2015 |
| Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| Standing Ovation | Standing Ovation produces animal-free dairy proteins using precision fermentation food technology. | Biotech | Paris, France | Series B | $28.6M | 2026-03-31 | $53.8M | Bpifrance, Seventure Partners, Big Idea Ventures +2 | 11 to 50 | 2021 |
| Orbem | Orbem provides AI-powered imaging and analytics for non-invasive biological insights. | Artificial intelligence | Munich, Germany | Series B | $64.6M | 2026-01-20 | $106.5M | European Innovation Council, Possible Ventures, 83North +1 | 101 to 250 | 2019 |
| Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg, Germany | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| Lattice Medical | Lattice Medical makes 3D printed bioabsorbable medical devices for breast reconstruction. | Biotech | Loos, France | Series B | $50.0M | 2025-10-24 | $63.3M | Bpifrance, European Innovation Council, MedTech Innovator +1 | 11 to 50 | 2017 |
| OXCCU | OXCCU converts carbon dioxide and hydrogen into synthetic fuels, chemicals, and biodegradable plastics. | Biotech | Oxford, United Kingdom | Series B | $27.9M | 2025-09-29 | $54.1M | IP Group, Aramco Ventures, Clean Energy Ventures +1 | 1 to 10 | 2021 |
| Cyted | Cyted uses AI and digital pathology to improve the detection and diagnosis of diseases, including cancer. | Artificial intelligence | Cambridge, United Kingdom | Series B | $44.0M | 2025-08-30 | $83.4M | Innovate UK, MedTech Innovator, Morningside +1 | 51 to 100 | 2018 |
| SNIPR Biome | SNIPR Biome develops discovery-stage biotech treatments for microbial diseases. | Biotech | Copenhagen, Denmark | Series B | $40.9M | 2025-08-07 | $103.4M | Wellington Partners, Bill & Melinda Gates Foundation, EQT Life Sciences +1 | 11 to 50 | 2017 |
| GlycoEra | GlycoEra researches and produces extracellular protein degraders for treating autoimmune diseases. | Biotech | Wädenswil, Switzerland | Series B | $130.0M | 2025-05-27 | $179.3M | Sofinnova Partners, Bristol-Myers Squibb, 5AM Ventures +1 | 11 to 50 | 2020 |
| TILT Biotherapeutics | TILT Biotherapeutics develops therapies that enable the immune system to attack tumors. | Biotech | Helsinki, Finland | Series B | $25.3M | 2025-05-13 | $71.1M | European Innovation Council, Business Finland, Lifeline Ventures +1 | 11 to 50 | 2013 |
| Seqera | Seqera provides tools that make complex data analysis scalable for genomics and global health research. | Biotech | Barcelona, Spain | Series B | $26.0M | 2025-05-06 | $53.0M | Creative Destruction Lab, Speedinvest, Talis Capital +1 | 101 to 250 | 2018 |
| Clinomic | Clinomic is a medical AI company focused on critical care. | Artificial intelligence | Aachen, Germany | Series B | $25.3M | 2025-04-08 | $54.6M | German Federal Ministry of Research, Technology and Space | 51 to 100 | 2019 |
| NETRI | NETRI develops technologies for the pharmaceutical industry. | Biotech | Lyon, France | Series B | $5.1M | 2025-02-02 | $5.1M | Next Innov Prize | 11 to 50 | 2018 |
| Noema Pharma | Noema Pharma develops therapies that treat disabling symptoms of brain and nervous system conditions. | Biotech | Basel, Switzerland | Series B | $147.2M | 2024-12-11 | $316.5M | Polaris Partners, Sofinnova Partners, Invus +2 | 11 to 50 | 2019 |
| Cradle | Cradle uses AI prediction algorithms to help biologists design proteins. | Artificial intelligence | Delft, The Netherlands | Series B | $73.0M | 2024-11-26 | Index Ventures, IVP, Kindred Capital | 11 to 50 | 2021 | |
| SynOx Therapeutics | SynOx Therapeutics is a biotechnology company developing treatments for diffuse tenosynovial giant cell tumors. | Biotech | Dublin, Ireland | Series B | $92.0M | 2024-10-30 | $245.9M | Forbion Capital Partners, Gimv, Hercules Capital +2 | 1 to 10 | 2020 |
| Qualifyze | Qualifyze provides global quality audit and site risk management solutions for life sciences companies. | Biotech | Frankfurt, Germany | Series B | $54.0M | 2024-09-10 | Insight Partners, APX, HV Capital +2 | 101 to 250 | 2019 | |
| CorFlow Therapeutics | CorFlow Therapeutics develops proprietary technologies to diagnose and treat microvascular obstructions. | Biotech | Baar, Switzerland | Series B | $48.5M | 2024-09-10 | $66.1M | Innosuisse, Unorthodox Ventures, Panakes Partners +2 | 11 to 50 | 2016 |
| Vico Therapeutics | Vico Therapeutics develops RNA modulating therapies. | Biotech | Leiden, The Netherlands | Series B | $12.3M | 2024-06-24 | $115.4M | Polaris Partners, Eurazeo, EQT Life Sciences +2 | 11 to 50 | 2019 |
| iOnctura | iOnctura is a clinical-stage biotechnology company developing treatments for cancer. | Biotech | Geneva, Switzerland | Series B | $85.7M | 2024-06-20 | European Innovation Council, M Ventures, VI Partners +2 | 11 to 50 | 2017 |
Table 1. Biotech startups that raised Series B in Europe: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 249.
Largest rounds
Last 12 months| # | Company | What they do | Sector | Location | Last round | Amount | Date | Total raised | Investors | Employees | Founded |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Windward Bio | Windward Bio develops monoclonal antibodies for advanced immunological diseases. | Biotech | Basel, Switzerland | Series B | $165.0M | 2026-05-04 | $365.0M | Qiming Venture Partners, OrbiMed, Novo Holdings +2 | 11 to 50 | 2024 |
| 2 | Vaderis Therapeutics | Vaderis Therapeutics develops targeted therapies for rare vascular diseases in clinical trials. | Biotech | Basel, Switzerland | Series B | $152.0M | 2026-08-11 | $170.6M | Medicxi | 11 to 50 | 2019 |
| 3 | T-Therapeutics | T-Therapeutics develops T cell receptor therapies, spun off from the University of Cambridge. | Biotech | Cambridge, United Kingdom | Series B | $133.0M | 2026-11-05 | $224.6M | F-Prime, Sofinnova Partners, Digitalis Ventures +2 | 51 to 100 | 2022 |
| 4 | Orbem | Orbem provides AI-powered imaging and analytics for non-invasive biological insights. | Artificial intelligence | Munich, Germany | Series B | $64.6M | 2026-01-20 | $106.5M | European Innovation Council, Possible Ventures, 83North +1 | 101 to 250 | 2019 |
| 5 | Exciva | Exciva develops clinical-stage biopharmaceutical therapies for neuropsychiatric symptoms of dementia. | Biotech | Heidelberg, Germany | Series B | $59.4M | 2026-01-20 | $69.8M | Andera Partners, LBBW VC, Cure8 Ventures | 1 to 10 | 2015 |
| 6 | Mironid | Mironid discovers drugs to treat degenerative kidney diseases, chronic inflammatory diseases, and cancer. | Biotech | Glasgow, United Kingdom | Series B | $45.9M | 2026-08-05 | $90.6M | Scottish Enterprise, Sofinnova Partners, European Investment Fund +1 | 11 to 50 | 2014 |
| 7 | NVision Quantum Technologies | NVision Quantum Technologies develops quantum-based imaging technology that enhances standard MRI systems. | Biotech | Ulm, Germany | Series B | $38.0M | 2026-05-13 | $155.2M | Entrée Capital, European Commission, Playground Global +2 | 101 to 250 | 2015 |
| 8 | Sava Technology | Sava Technology creates under-skin sensors that continuously monitor glucose, lactate, and ketones. | Biotech | London, United Kingdom | Series B | $36.0M | 2026-10-09 | $62.8M | SOSV, Balderton Capital, Social Starts +1 | 101 to 250 | 2016 |
| 9 | NovaGo Therapeutics | NovaGo Therapeutics is a Swiss biotech company developing human antibody therapeutics to promote regeneration after cerebral stroke. | Biotech | Schlieren, Switzerland | Series B | $29.7M | 2026-08-31 | $39.7M | Kinled Holding, Pureos Bioventures | 1 to 10 | 2015 |
| 10 | Standing Ovation | Standing Ovation produces animal-free dairy proteins using precision fermentation food technology. | Biotech | Paris, France | Series B | $28.6M | 2026-03-31 | $53.8M | Bpifrance, Seventure Partners, Big Idea Ventures +2 | 11 to 50 | 2021 |
Table 2. Biotech startups that raised Series B in Europe: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most active investors
By companies backed| # | Investor | Type | Location | Companies | Share | Funded, 12 months | Latest |
|---|---|---|---|---|---|---|---|
| 1 | HTGF (High-Tech Gruenderfonds) | Venture capital firm | Bonn, Germany | 16 | 6% | 1 | Computomics |
| 2 | European Innovation Council | Startup accelerator | Brussels, Belgium | 8 | 3% | 3 | Onego Bio, Computomics, Orbem |
| 3 | Sofinnova Partners | Venture capital firm | Paris, France | 6 | 2% | 2 | T-Therapeutics, Mironid |
| 4 | Bpifrance | Government investment office | Maisons-alfort, France | 6 | 2% | 1 | Standing Ovation |
| 5 | Andera Partners | Private equity firm | Paris, France | 6 | 2% | 1 | Exciva |
| 6 | EQT Life Sciences | Private equity firm | Amsterdam, The Netherlands | 6 | 2% | ||
| 7 | Forbion Capital Partners | Private equity firm | Naarden, The Netherlands | 5 | 2% | ||
| 8 | Innovate UK | Entrepreneurship program | Swindon, United Kingdom | 4 | 2% | ||
| 9 | Bristol-Myers Squibb | Venture capital firm | New York, United States | 4 | 2% | ||
| 10 | Index Ventures | Venture capital firm | San Francisco, United States | 4 | 2% | ||
| 11 | Venture Kick | Startup incubator | Schlieren, Switzerland | 4 | 2% | ||
| 12 | VI Partners | Venture capital firm | Altendorf, Switzerland | 4 | 2% | ||
| 13 | KfW | Government investment office | Frankfurt, Germany | 4 | 2% | ||
| 14 | NRW.BANK | Government investment office | Düsseldorf, Germany | 4 | 2% | ||
| 15 | Boehringer Ingelheim Venture Fund | Corporate venture arm | Ingelheim Am Rhein, Germany | 4 | 2% |
Table 3. Biotech startups that raised Series B in Europe: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Sectors
| Sectors | Companies | Share | Total raised |
|---|---|---|---|
| Health care | 197 | 79% | $6.6B |
| Software | 22 | 9% | $641.5M |
| Artificial intelligence | 11 | 4% | $384.0M |
| Hardware | 5 | 2% | $195.9M |
| Cybersecurity | 2 | 1% | $25.7M |
| Education | 2 | 1% | $284.5M |
| Fintech | 2 | 1% | |
| Energy | 1 | 0% | $54.1M |
| Commerce | 1 | 0% |
Table 4. Biotech startups that raised Series B in Europe by sector. Source: FundingWatcher. Data as of 16 November 2026.
Funding stage
| Funding stage | Companies | Share | Median last round |
|---|---|---|---|
| Series B | 249 | 100% | $20.0M |
Table 5. Biotech startups that raised Series B in Europe by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Countries
| Countries | Companies | Share |
|---|---|---|
| United Kingdom | 72 | 29% |
| France | 38 | 15% |
| Germany | 35 | 14% |
| Switzerland | 31 | 12% |
| The Netherlands | 14 | 6% |
| Belgium | 13 | 5% |
| Spain | 10 | 4% |
| Ireland | 10 | 4% |
| Italy | 8 | 3% |
| Denmark | 7 | 3% |
| Finland | 5 | 2% |
| Sweden | 4 | 2% |
Table 6. Biotech startups that raised Series B in Europe by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.
Cities
| Cities | Companies | Share |
|---|---|---|
| London | 23 | 9% |
| Cambridge | 15 | 6% |
| Paris | 14 | 6% |
| Oxford | 9 | 4% |
| Basel | 7 | 3% |
| Dublin | 7 | 3% |
| Munich | 5 | 2% |
| Geneva | 5 | 2% |
| Madrid | 5 | 2% |
| Schlieren | 4 | 2% |
| Barcelona | 4 | 2% |
| Milan | 3 | 1% |
Table 7. Biotech startups that raised Series B in Europe by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.
Rounds by month
| Rounds by month | Companies | Share | Raised |
|---|---|---|---|
| November 2026 | 1 | 5% | $133.0M |
| October 2026 | 3 | 14% | $90.0M |
| September 2026 | 1 | 5% | $70.8M |
| August 2026 | 5 | 23% | $250.4M |
| July 2026 | 1 | 5% | $65.0M |
| June 2026 | 4 | 18% | $168.6M |
| May 2026 | 2 | 9% | $203.0M |
| March 2026 | 1 | 5% | $28.6M |
| January 2026 | 4 | 18% | $159.2M |
Table 8. Biotech startups that raised Series B in Europe: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.
Most recent round by year
| Most recent round by year | Companies | Share | Raised |
|---|---|---|---|
| 2026 | 22 | 9% | $1.2B |
| 2025 | 30 | 12% | $1.5B |
| 2024 | 29 | 12% | $1.4B |
| 2023 | 14 | 6% | $329.2M |
| 2022 | 17 | 7% | $624.0M |
| 2021 | 19 | 8% | $952.9M |
Table 9. Biotech startups that raised Series B in Europe by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.
Founding year
| Founding year | Companies | Share |
|---|---|---|
| 2023 or later | 2 | 1% |
| 2020 to 2022 | 19 | 8% |
| 2015 to 2019 | 83 | 33% |
| 2010 to 2014 | 56 | 23% |
| Before 2010 | 88 | 35% |
Table 10. Biotech startups that raised Series B in Europe by founding year. Source: FundingWatcher. Data as of 16 November 2026.
Team size
| Team size | Companies | Share |
|---|---|---|
| 1 to 10 | 56 | 23% |
| 11 to 50 | 135 | 55% |
| 51 to 100 | 33 | 13% |
| 101 to 250 | 17 | 7% |
| 251 to 500 | 1 | 0% |
| 501 to 1,000 | 1 | 0% |
| 1,001 to 5,000 | 1 | 0% |
| 10,001 or more | 1 | 0% |
Table 11. Biotech startups that raised Series B in Europe by headcount. Source: FundingWatcher. Data as of 16 November 2026.
Method
- A company is on this list when Biotech is one of its sectors and its most recent funding round is Series B and its headquarters is in Europe. On 16 November 2026 that is 249 companies.
- Stage, round, amount and date are those of the company's most recent funding round. Amounts are in US dollars as the source records them.
- The table prints the 30 newest rounds whose row is complete: a one-sentence description, a city, a named fund and an amount. The CSV carries all 249 rows: 18 have no round amount, 0 no city and 85 no website. The CSV carries domain, website, LinkedIn and the cached description sentence where present.
Sources, fields and exclusions of both files: Method.
Questions
- How many biotech startups in Europe whose last round is Series B are on the list?
- 249, in the file dated 16 November 2026. 22 of them closed their most recent round in the last 12 months.
- What does the CSV contain?
- One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
- How much does the list cost?
- $29 one-time for all 249 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
- What arrives after payment?
- At once: the CSV download link, on the page after payment and by mail.
- Can I see rows before buying?
- The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
- How current is the data?
- The file is dated 16 November 2026. The download link serves the current file each time it is opened.
Not sure about the data?
Download a free 10-row sample first. No account, no payment.